Medicus Pharma (NASDAQ:MDCX) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Medicus Pharma (NASDAQ:MDCX) issued its earnings results on Thursday. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.13), Zacks reports.

Medicus Pharma Stock Down 10.7%

Shares of NASDAQ MDCX opened at $0.30 on Friday. The firm has a market cap of $12.59 million, a price-to-earnings ratio of -0.11 and a beta of -0.47. Medicus Pharma has a 52-week low of $0.25 and a 52-week high of $8.94. The business’s 50 day moving average is $0.41 and its two-hundred day moving average is $1.23.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MDCX. Weiss Ratings reiterated a “sell (e+)” rating on shares of Medicus Pharma in a report on Friday, April 10th. Roth Mkm began coverage on Medicus Pharma in a report on Tuesday, April 21st. They issued a “buy” rating on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Medicus Pharma in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Medicus Pharma currently has an average rating of “Hold” and an average price target of $9.00.

Institutional Trading of Medicus Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new stake in Medicus Pharma in the fourth quarter valued at approximately $2,771,000. Jane Street Group LLC purchased a new stake in Medicus Pharma in the fourth quarter valued at approximately $92,000. HRT Financial LP purchased a new stake in Medicus Pharma in the fourth quarter valued at approximately $42,000. Commonwealth Equity Services LLC raised its position in Medicus Pharma by 161.8% in the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares during the period. Finally, Wilmington Savings Fund Society FSB increased its position in shares of Medicus Pharma by 100.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock worth $78,000 after acquiring an additional 25,622 shares during the period.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.